This research improves combination vaccines by addressing antigen competition using injectable hydrogels that slowly release antigens. This approach produces balanced immune responses to multiple diseases, unlike traditional vaccines. The innovation could reduce the number of shots required, improve global vaccine access, and ensure more effective immunization, particularly in underserved populations.

This research explores how mast cells—immune cells responsible for allergy symptoms—can be repurposed to strengthen vaccines. By targeting mast cells with nasal vaccines, stronger and longer-lasting immune responses may be generated, particularly benefiting high-risk populations and improving protection against infectious diseases.